Intranasal nano-immunotherapy for glioma: bypassing the blood–brain barrier, reprogramming the immune microenvironment, and bridging preclinical validation
Glioma, particularly glioblastoma, remains difficult to treat because of limited drug penetration across the blood–brain barrier, profound immune suppression, and insufficient intracranial exposure of systemic immunotherapies. Intranasal nano-immunothe…